PROTAC HPK1 Degrader-1 is a proteolysis-targeting chimera (PROTAC) designed to induce targeted degradation of hematopoietic progenitor kinase 1 (HPK1), also known as MAP4K1. HPK1 is an intracellular kinase involved in the regulation of T-cell and other immune-cell signaling pathways and has attracted interest as a potential target in cancer immunotherapy. The chemical name of PROTAC HPK1 Degrader-1 is 4-((2-(3-(4-(4-(3-(3,4-dimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl)piperazin-1-yl)-3-oxopropoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione. The compound is designed to facilitate recruitment of an E3 ubiquitin ligase to HPK1, promoting ubiquitination and subsequent degradation of the target protein through the ubiquitin–proteasome system.
PROTAC HPK1 Degrader-1 has a CAS No. of 3034182-97-0, a molecular formula of C₄₃H₄₃N₇O₈, and a molecular weight of 785.84 g/mol. It is intended for research applications involving HPK1/MAP4K1 degradation, targeted protein degradation, PROTAC technology, T-cell signaling, immune regulation, cancer immunotherapy, and tumor biology. The compound can be used as a research tool for investigating HPK1-dependent signaling pathways and the biological effects of targeted HPK1 depletion. For research use only.
关键字： PROTAC;HPK1 degrader;cancer immunotherapy;cancer research;
杭州埃米尔生物技术有限公司位于浙江省杭州市钱塘区下沙街道安和药谷，立足杭州生物医药产业集聚区位优势，专注深耕ADC/XDC 生物偶联技术研发服务、医药小分子中间体定制合成两大核心业务，是聚焦抗体偶联药物上下游研发配套的专业化生物技术初创企业，面向药企、CRO 公司、高校科研院所提供从工艺开发、样品合成到质控分析的一站式技术外包解决方案。